Rubius Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Rubius Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q4 2022.
  • Rubius Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2022 was -$23.1M, a 57% increase year-over-year.
  • Rubius Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2022 was -$178M, a 8.31% increase year-over-year.
  • Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$178M, a 8.31% increase from 2021.
  • Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$195M, a 16.9% decline from 2020.
  • Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2020 was -$166M, a 1.86% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 -$178M -$23.1M +$30.6M +57% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-27
Q3 2022 -$209M -$61.6M -$11.5M -23% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-09
Q2 2022 -$198M -$42.9M +$7.02M +14.1% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-09
Q1 2022 -$205M -$50.9M -$9.95M -24.3% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-10
Q4 2021 -$195M -$53.7M -$14M -35.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-27
Q3 2021 -$181M -$50M -$9.86M -24.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$171M -$49.9M -$12.2M -32.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$159M -$40.9M +$7.93M +16.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$166M -$39.7M +$5.71M +12.6% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-23
Q3 2020 -$172M -$40.2M +$8.3M +17.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$180M -$37.7M +$3.59M +8.69% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$184M -$48.9M -$14.4M -42% Jan 1, 2020 Mar 31, 2020 10-Q/A 2021-08-20
Q4 2019 -$170M -$45.4M -$16.3M -56% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 -$153M -$48.5M -$20.9M -76% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-23
Q2 2019 -$132M -$41.3M -$20.9M -103% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-23
Q1 2019 -$111M -$34.4M -$19.8M -136% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-23
Q4 2018 -$91.7M -$29.1M -$11.6M -66.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$80M -$27.6M -$15.6M -130% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$64.4M -$20.4M -$11.4M -126% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$53.1M -$14.6M -$9.82M -205% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$43.3M -$17.5M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-28
Q3 2017 -$12M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-28
Q2 2017 -$9.03M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-28
Q1 2017 -$4.78M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.